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and correlated positively with osteoblast number and nega-The pathogenesis of osteodystrophy after renal transplantation
tively with the number of apoptotic osteoblasts. In addition,as detected by early alterations in bone remodeling.
posttransplant osteoblast surface correlated positively withBackground. Loss of bone mass after transplantation begins
parathyroid hormone (PTH) levels and negatively with gluco-in the early periods after transplantations and may persist for
corticoid cumulative dose.several years, even in patients with normal renal function.
Conclusion. The data suggest that impaired osteoblastogen-While the pathogenesis of these abnormalities is still unclear,
esis and early osteoblast apoptosis may play important roles inseveral studies suggest that preexisting bone disease, glucocor-
the pathogenesis of posttransplant osteoporosis. The possibleticoid therapy, and alterations in phosphate metabolism may
mechanisms involved in the pathogenesis of theses alterationsplay important roles. Recent studies indicate that osteoblast
include posttransplant hypophosphatemia, the use of glucocor-apoptosis and impaired osteoblastogenesis play important roles
ticoids, and the preexisting bone disease. PTH seems to havein the pathogenesis of glucocorticoid-induced osteoporosis.
a protective effect by preserving osteoblast survival.Objectives. To examine the early alterations in osteoblast
number and surfaces during the period following renal trans-
plantation.
Methods. Twenty patients with a mean age of 36.5  12
Bone mass loss after transplantation is a well-describedyears were subjected to bone biopsy 22 to 160 days after renal
phenomenon that starts in the early periods after trans-transplantation. In 12 patients, a control biopsy was performed
on the day of transplantation. Bone sections were evaluated plantations and may persist for several years, even in
by histomorphometric analysis and cell DNA fragmentation patients with normal renal function [1–6]. While the
by the methods of terminal deoxynucleotidyl transferase-medi- pathogenic mechanisms of these abnormalities are still
ated uridine triphosphate nick end labeling (TUNEL), using
unclear, several studies suggest that preexisting boneimmunoperoxidase and direct immunofluorescence techniques.
diseases, immunosuppressive drugs [1–6], persistently el-Results. The main alterations in posttransplant biopsies were
a decrease in osteoid and osteoblast surfaces, adjusted bone evated levels of parathyroid hormone (PTH) [6–9] and
formation rate, and prolonged mineralization lag time. Peri- alterations of phosphate metabolism [10, 11] may play
trabecular fibrosis was markedly decreased. None of the pre- important roles. From the majority of published studies,
transplant biopsies revealed osteoblast apoptosis. In contrast,
the main bone alterations in bone remodeling after renalTUNEL-positive cells in the proximity of osteoid seams or in the
transplantation are changes (decrease) in bone forma-medullary space were observed in nine posttransplant biopsies
of which four had mixed bone disease, two had adynamic bone tion in the face of persistent bone resorption. This pro-
disease, one had osteomalacia, one had osteitis fibrosa, and one duces an imbalance in remodeling favoring resorption
had mild hyperparathyroid bone disease. Osteoblast number in [4–6]. Therefore, it is possible that the defective bone
posttransplant biopsies with apoptosis was lower as compared
formation may be a consequence of either alterations inwith posttransplant biopsies without apoptosis. In addition,
osteoblast function, decreased generation, or increasedmost of them showed a marked shift toward quiescence from
the cuboidal morphology of active osteoblasts. Serum phospho- osteoblast death rates. There is evidence suggesting that
rus levels were lower in patients showing osteoblast apoptosis under normal conditions, osteoblast number at the be-
ginning of a remodeling period differs markedly at the
end of the same cycle, suggesting that an important num-Key words: renal transplantation, bone histopathology, parathyroid
ber of cells undergo apoptosis [12]. Furthermore, recenthormone, renal osteodystrophy, transplant bone disease, bone cell
apoptosis, osteoblast apoptosis, posttransplant bone disease. studies in mice indicate that glucocorticoids promote
osteoblast and osteocyte apoptosis and inhibit osteo-Received for publication May 8, 2002
blastogenesis, resulting in the defective bone formationand in revised form August 31, 2002, and November 10, 2002
Accepted for publication January 3, 2003 observed in glucocorticoid-induced osteoporosis [13].
Conversely, it has been shown that in mice with osteope- 2003 by the International Society of Nephrology
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nia due to defective osteoblastogenesis, PTH increases kidney from cadaveric donors, only a posttransplant
biopsy was performed. In 17 patients, the time elapsedbone formation by preventing osteoblast apoptosis [14].
Based on these observations, the present study was de- from the date of transplantation to bone biopsy ranged
from 22 to 60 days (35  14 days), and 90 to 160 dayssigned to examine the possible role of an early increase
in osteoblast apoptosis and alterations in osteoblastogen- (135.6 31 days) in the remaining three patients. Double
tetracycline labeling was obtained in 11 posttransplantesis, as well as the influence of preexisting bone disease
in the histomorphometric alterations in bone after trans- biopsies.
Undecalcified bone specimens were fixed in ethanol,plantation. The studies were performed shortly after re-
nal transplantation, a period in which patients are ex- included in methyl methacrylate and cut for histomor-
phologic examination. Sections were stained by the Mas-posed to high doses of glucocorticoids and in which some
of the preexisting alterations of bone metabolism may son-Goldner trichromic method [15]. Aluminum was
stained by the aurin tricarboxylic acid method [16], andstill be present.
iron by the Perls’ method [17]. Histomorphometric anal-
ysis was performed using light microscopy, a Merz Schaenk
METHODS
reticle, and an eyepiece micrometer [18]. Static and dy-
Patients namic parameters of bone structure are expressed accord-
ing to the American Society of Bone and Mineral Re-Twenty patients participated in a prospective study to
evaluate the early bone alterations occurring after renal search (ASMBR) nomenclature committee [19]. The
normal reference values used [20–28] are in general agree-transplantation. All patients signed informed consent.
Exclusion criteria were persistent posttransplant renal ment with data obtained for normal Latin American
population [abstract; Jorgetti V et al, Bone 23 (Suppl 5):insufficiency requiring dialysis and sepsis. There were 12
men and eight women with a mean age of 36.5 12 years. S476, 1998].
Patients had been on dialysis prior to transplantation
Detection of apoptosisfor 21.4  7.3 months. The underlying kidney diseases
Bone sections were examined for cell DNA fragmenta-leading to end-stage renal diseases were chronic glomer-
tion by the methods of terminal deoxynucleotidyl trans-ulonephritis (N 9), nephrosclerosis (N 2), polycystic
ferase-mediated uridine triphosphate nick end labelingkidney disease (N  2), urolithiasis (N  1), and un-
(TUNEL) using both immunoperoxidase and direct im-known (N 6). Posttransplant immunosuppressive ther-
munofluorescence techniques. For immunoperoxidaseapy consisted of glucocorticoids, cyclosporine, and myco-
studies, undecalcified sections were deplasticized andphenolate mofetil. Acute rejection occurred in four
treated with 5 g/mL proteinase K for 15 minutes at roompatients and was treated with intravenous methylpreni-
temperature. Endogenous peroxidase was quenched withsolone pulse for 3 consecutive days. None of the patients
3% H2O2 in phosphate-buffered saline (PBS) for 5 min-received glucocorticoids, immunosuppressant drugs, vi-
utes. Terminal deoxynucleotidyl transferase (TdT) (Apo-tamin D or analogs, bisphosphonates, or other drugs
ptag Plus Peroxidase In Situ Apoptosis Detection Kit,associated with alterations of bone metabolism during
Intergen Co., New York, NY, USA) and digoxigenin-the dialysis period.
labeled uridine triphosphate (dUTP) were added and
sections were incubated for 1 hour at 37C. TUNELBiochemical determinations
signal was detected with peroxidase-labeled antidigoxi-Serum samples were obtained at time of bone biopsies
genin antibody and developed with diaminobenzidine.for biochemical determinations. Calcium, phosphorus,
Sections were counterstained with methyl green.
creatinine, and total alkaline phosphatase were deter- For direct immunofluorescence studies, deplasticized
mined by routine laboratory techniques. Bone-specific bone sections were rehydrated and treated with 20
alkaline phosphatase was assessed by enzyme-linked im- g/mL proteinase K in PBS for 15 minutes at room
munosorbent assay (ELISA) (Metra Biosystem, Inc., temperature. Sections were rinsed twice with PBS. Equil-
Mountain View, CA, USA). Intact PTH levels were de- ibration buffer was added directly to the specimens. Sam-
termined by immunoradiometric analysis (AllegroTM; ples were labeled according to the instruction of the
Nichols Institute, San Juan Capistrano, CA, USA). Se- commercial kit (Apoptag Fluoroscein Direct In Situ
rum osteocalcin was determined using an immunoradio- Apoptosis Detection Kit, Intergen Co., New York, NY,
metric assay (Nichols Institute). USA). Briefly, tissue sections were covered with the
TUNEL reaction mixture and incubated in a dark hu-
Bone biopsies and bone histology midified chamber at 37C for 60 minutes. The slides were
Transiliac bone biopsies were performed at the ante- rinsed twice with stop/wash buffer for 20 minutes and
rior iliac crest using a Bordier needle. In 11 patients, mounted with glass coverslip and mounting media. The
a control biopsy was performed on the same day of slides were viewed using a fluorescent microscope.
Weaned rat mammary tissue, supplied by the manufac-transplantation. In the remaining nine patients, receiving
Rojas et al: Early alterations in posttransplant bone remodeling 1917
Table 2. Histomorphometric parameters in pre- and posttransplantTable 1. Serum biochemical and hormonal parameters in 20 patients
at the times of pre- and posttransplant bone biopsies bone biopsies
NormalMean
reference
Parameter Pretransplant Posttransplant P value Parameter Pretransplant Posttransplant valuesa
Calcium mg/dL 9.20.8 8.90.7 NS Bone volume/tissue
Phosphorus mg/dL 5.11.4 2.80.25 0.01 volume % 24.74.8 22.85.1 21.25.1
Total alkaline Osteoid volume/
phosphatase U/dL 151115 13946 NS tissue volume % 6.74.03 6.014.4 2.71.8
Bone alkaline Osteoid surface/
phosphatase 7634 4128 NS bone surface % 46.216.9b 32.715.0 14.27.7
Osteocalcin nmol/mL 15925 10388 NS Erosion surface/
Parathyroid hormone bone surface % 13.14.3 11.85.5 3.61.1
pg/mL 593760 174240 0.05 Osteoclast surface/
bone surface % 8.03.5 5.83.3 0.60.1Results are expressed as meanSD.
Osteoblast surface/
bone surface % 22.19.4c 15.810.9 4.91.4
Osteoid thickness lm 15.36.3 15.35.7 10.01.8
Osteoblast number/
turer, was used as a positive control. Negative controls tissue surface mm2 0.330.17 0.130.11
Fibrosis surface/were made by omitting the transferase from the reaction
bone surface % 16.129.2 6.918.1 0mixture [23]. Mineralizing surface/
bone surface % 12.62.9 188
Statistical analysis Mineral apposition
rate l/day 0.70.14 0.650.1Results are expressed as mean  standard deviation. Bone formation rate/
Statistical analysis was performed by Student t test and bone surface l3/l2/day 0.080.04 0.130.07
Adjusted bone formationmultiple regression analysis. P  0.05 was considered
rate l3/l2/day 0.290.15 0.50.2significant. Mineralization lag time
days 57.348 21.32
Results are expressed as meanSD.RESULTS aData from references [19–21]
bP  0.01Biochemical determinations
cP  0.05
The results of blood biochemical analysis of the 20
patients are shown in Table 1. There were no statistical
significant differences in calcium, total alkaline phospha- and osteoclast surface were above the normal range in
pretransplant biopsies, remaining unchanged after trans-tase, bone specific alkaline phosphatase, and osteocalcin
pre- and posttransplantation. However, phosphorus (5.1 plantation. In contrast, osteoid and osteoblast surfaces
were elevated in pretransplant biopsies, but decreased1.4 mg/dL vs. 2.8 0.25 mg/dL, P 0.01) and PTH (593
760 pg/mL vs. 174  240 pg/mL, P  0.05) decreased significantly after transplantation.
To further examine the effects of transplantation onsignificantly after transplantation. Serum creatinine at
the time of posttransplant biopsies was within the normal bone histomorphometry, we compared static parameters
in paired biopsies performed in 11 patients at the timerange (1.3  0.2 mg/dL).
of transplantation and 60 38 days after transplantation.
Bone histology As shown in Figure 1, osteoid and osteoblast surfaces
decreased significantly after transplantation. In addition,The histologic diagnosis in the whole group of patients
were as follows: five had osteitis fibrosa, two had mild peritrabecular fibrosis decreased markedly or disap-
peared. All other posttransplant parameters did nothyperparathyroidism, six had mixed bone disease, three
had adynamic bone disorder, two had osteoporosis, one show significant changes compared with pretransplant
biopsies. Similar results were obtained when histomor-had osteomalacia, and one had normal bone histology.
Aluminum in more than 30% of bone trabeculae was phometric parameters in pretransplant biopsies were
compared with those of the whole group of 20 patientsfound only in two patients, both of them with mixed
bone disease. studied posttransplant, but, as expected, paired biopsies
corrected for the variable forms of renal osteodystrophy,Histomorphometric parameters. Table 2 shows the
histomorphometric parameters in pre- and posttrans- increasing the significance of the changes due to trans-
plantation.plant bone biopsies in the whole group of patient com-
pared with normal reference values [20–22]. Trabecular Bone dynamic histomorphometric parameters were
determined in 11 patients that underwent posttransplantbone volume was within the normal range and remained
unchanged in this early period following transplantation. double tetracycline labeling (four patients had mixed
bone disease, two had adynamic bone disease, three hadOsteoid volume, osteoid thickness, resorption surface,
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Table 3. Posttransplant osteoblast apoptosis according with the type
of bone disease
Bone disease Total Apoptosis No apoptosis
Adynamic bone disease 3 2 1
Osteomalacia 1 1 0
Mixed bone disease 6 4 2
Mild hyperparathyroidism 2 1 1
Osteitis fibrosa 5 1 4
Osteoporosis 2 0 2
Normal histomorphometry 1 0 1
Total 20 9 11
addition, there was a change in osteoblast morphology,
demonstrating a marked shift toward quiescence or inac-
tive form from the cuboidal morphology of active osteo-
blasts, even in the presence of elevated osteoid thickness
in many patients, suggesting defective mineralization.
Fig. 1. Comparison of static histomorphometric parameters of 11 Figure 3B shows a highly significant correlation between
paired bone biopsies performed at the times of transplantation (pre-
total osteoblast number and active osteoblasts. Thus,Tx) and 38  17 days after transplantation (post-Tx). The numbers are
expressed as mean  standard deviation. patients with lower osteoblast number had also a lesser
number of active osteoblasts. In favor of these observa-
tions, patients with osteoblast apoptosis showed a sig-
nificant decrease in posttransplant serum osteocalcin lev-
hyperparathyroid bone disease, one had osteoporosis, els (Fig. 4).
and one had normal bone histology). As shown in Table Osteoblast apoptosis and serum phosphorus. To ex-
2, all dynamic parameters were below the normal refer- amine the possible causes of increased posttransplant apo-
ence values. However, the most prominent changes were ptosis, we compared the pre- and posttransplant serum
a reduction in adjusted bone formation rate and a mark- biochemical parameters in patients with or without osteo-
edly prolonged mineralization lag time compatible with blast apoptosis. An interesting observation was an associa-
the changes in osteoblast and osteoid surface shown in tion between posttransplant osteoblast apoptosis and se-
Figure 1. rum phosphorus (Fig. 5A). Thus, serum phosphorus
Osteoblast apoptosis. All pre- and posttransplant bi- levels were significantly lower in patients with biopsies
opsies were examined for apoptosis using the method of showing osteoblast apoptosis (2.3  0.4 mg/dL vs. 3.4 
TUNEL. None of the pretransplant biopsies showed 0.8 mg/dL in apoptosis-negative biopsies, P  0.01).
bone cell apoptosis by these techniques. In contrast, as To examine a possible effect of phosphorus on osteo-
shown in Table 3, TUNEL-positive cells were observed blast genesis or survival, we correlated osteoblast num-
in nine posttransplant biopsies, of which four had mixed ber and serum phosphorus levels in all patients studied.
bone disease, two had adynamic bone disease, one had As shown in Figure 5B, there was a highly significant
osteomalacia, one had osteitis fibrosa, and one had mild correlation between posttransplant osteoblast number
hyperparathyroid bone disease (Table 3). This phenome- and serum phosphorus (r, 0.621; P 0.01). Furthermore,
non appeared to be independent of the time elapsed the number of posttransplant apoptotic cells in the biop-
between transplantation and posttransplant biopsy. Fig- sies correlated negatively with posttransplant serum
ure 2 shows representative preparations of bone biopsies phosphorus (r, 0.641; P  0.01).
with TUNEL-positive cells. TUNEL-positive osteoblasts In agreement with previous studies [11], the changes
were clearly observed in the proximity of osteoid seams in serum phosphorus were independent of PTH, since
(Fig. 2 A to C). TUNEL-positive osteocytes were ob- posttransplant PTH levels in both groups were similar
served in one of the biopsies from a patient with ady- (105.5 47.4 pg/mL vs. 130.3 119 pg/mL, NS) and there
namic bone disease (Fig. 2D). In addition, in the majority was no correlation between the serum hormone levels
of specimens, numerous apoptotic bodies were observed and phosphorus pre- or posttransplantation (Fig. 6).
free or within macrophages in the bone marrow space. Effect of PTH and glucocorticoids. As a means to
Osteoclast apoptosis was not observed. evaluate the possible effect of PTH on posttransplant
As shown in Figure 3A, the total osteoblast number alterations in bone remodeling, we examined the correla-
per tissue surface in posttransplant biopsies with apopto- tion of pre- or posttransplant levels of the hormone with
sis was lower as compared with those without apoptosis the different histomorphometric parameters in post-
transplant bone specimens. The main findings were a(0.15  0.09/mm2 vs. 0.35  0.17/mm2, P  0.01). In
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Fig. 2. Representative microphotograph of bone biopsies showing cell apoptosis by the method of terminal deoxynucleotidyl transferase-mediated
uridine triphosphate nick end labeling (TUNEL). (A ) Direct immunofluorescence staining of a biopsy of a patient with mixed bone disease showing
TUNEL-positive osteoblasts. (B ) Direct immunofluorescence staining of a biopsy from a patient with osteomalacia showing apoptotic bodies in
the proximity of osteoid seams. (C ) Direct immunofluorescence staining showing apoptotic osteocytes. (D ) Immunoperoxidase staining of a biopsy
of a patient with osteitis fibrosa showing TUNEL-positive cells in the proximity of osteoid seams. BT is bone trabeculae.
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Fig. 4. Posttransplant serum osteocalcin levels in patients showing apo-
ptosis compared with patients without osteoblast apoptosis in posttrans-
plant bone biopsies. The numbers are expressed as mean  standard
deviation.
Fig. 3. (A) Osteoblast number per tissue surface in bone biopsies of
patients showing osteoblast apoptosis (Apoptosis, N  9) compared
with those without evident apoptosis (No apoptosis, N  11). The
numbers are expressed as mean  standard deviation. (B ) Correlation
between the total number and the number of active osteoblasts as
determined by the typical cuboidal morphology.
highly significant positive correlation between pretrans-
plant PTH levels and posttransplant osteoblast surface
(Fig. 7A), as well as a correlation between posttransplant
PTH and osteoblast surface. Thus, patients with higher
pretransplant or posttransplant PTH levels showed a
larger osteoblast surface than those with low PTH. In Fig. 5. (A) Posttransplant serum phosphorus levels in patients showing
apoptosis compared with patients without osteoblast apoptosis in post-contrast, there was a negative correlation between gluco-
transplant bone biopsies. (B ) Relationship between serum phosphoruscorticoid cumulative dose and posttransplant osteoblast and apoptosis of osteoblasts.
surface (Fig. 8).
There was no correlation between cyclosporine or my-
cophenolate mofetil cumulative doses and the histomor-
sist for years [1–4]. However, the mechanisms remainphometric alterations observed in posttransplant biop-
unclear. Therefore, the present studies were designed tosies or serum biochemical changes in our patients.
examine the histologic bone changes occurring in the
early period that follows renal transplantation. The re-
DISCUSSION sults demonstrate early posttransplant apoptosis of os-
teoblasts and a decrease in osteoblast number and sur-Previous studies suggest that the bone loss observed
after renal transplantation may start very early and per- face, as well as a decrease in bone formation rate and a
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Fig. 8. Correlation between the posttransplant cumulative dose of glu-
cocorticoids and osteoblast surface.
Fig. 6. Correlation between posttransplant serum phosphorus and
parathyroid hormone (PTH) levels.
coids, seem to play a role in the pathogenic mechanisms
leading to these alterations.
Pretransplant biopsies showed different histologic ab-
normalities, including osteitis fibrosa, mixed and ady-
namic bone disease, osteomalacia, and osteoporosis.
Most of the patients showed a decrease in posttransplant
osteoblast surfaces and number independent of the pre-
dominant bone disease. Thus, reduced osteoblast sur-
faces were observed in patients with low bone turnover,
as well as in those with high bone turnover. A striking
finding was a marked tendency to change from the typical
cuboidal osteoblast morphology to the quiescent status,
indicating an early decrease in osteoblast activity after
transplantation. Indeed, most osteoblasts looked quies-
cent, even in presence of increased osteoid surface and
thickness, resulting in a decreased bone formation rates
and prolonged mineralization lag time in the majority
of patients who underwent double tetracycline labeling
after transplantation. These alterations in bone turnover
are similar to those observed in patients with long-term
renal transplantation [4], including the development of
generalized or focal osteomalacia in many of them [6],
suggesting that the pathogenic mechanisms involved
start operating early and are maintained for years after
transplantation.
Recent studies have demonstrated that osteoblasts, in
addition to becoming lining cells and osteocytes, undergo
apoptosis with a frequency sufficient to explain the dif-
ference in the number of osteoblasts in remodeling bone
Fig. 7. Correlation between serum parathyroid hormones (PTH) levels [24]. Furthermore, it has been demonstrated that in-
and osteoblast surface. (A) Correlation between pretransplant serum creased apoptosis and reduced osteoblastogenesis mayPTH levels and posttransplant osteoblast surface. (B ) Correlation be-
be one of the main mechanisms of glucocorticoid-in-tween posttransplant serum PTH levels and posttransplant osteoblast
surface. duced osteoporosis. In our study, none of the pretrans-
plant biopsies examined showed osteoblast apoptosis.
However, nine of the patients studied showed osteoblastdelayed mineralization lag time, suggesting that impaired
apoptosis in the early period after transplantation. Theseosteoblast number and function may play a role in the
patients also showed lower osteoblast surface and num-pathogenesis of posttransplant bone disease. Several fac-
ber. There were no differences in posttransplant timetors, including the preexisting bone disorder, alterations
in mineral metabolism, as well as the use of glucocorti- between patients showing apoptosis compared with
Rojas et al: Early alterations in posttransplant bone remodeling1922
those in which this phenomenon could not be demon- tively low levels of 1,25(OH)2 vitamin D3. However,
recent studies strongly suggest the presence of a circulat-strated, indicating that the increase in apoptosis in these
patients cannot be attributed to the time elapsed after ing humoral factor (phosphatonin) that induces phos-
phaturia independent of PTH [31, 32]. The fact thattransplantation. In contrast, the preexisting bone disease
seems to play a role, since osteoblast apoptosis was more we did not find correlation between serum phosphorus
levels with PTH or glucocorticoid cumulative dose sug-frequently observed in patients with adynamic bone dis-
ease, osteomalacia, and mixed bone disease, whereas it gests that this phosphaturic humoral factor could be in-
volved in the posttransplant hypophosphatemia observedwas relatively rare in patients with high bone turnover.
It is important to mention that, although apoptosis is a in our patients. Indeed, recent studies demonstrate that
serum obtained from patients early after transplantationnatural phenomenon, it is difficult to demonstrate since
apoptotic bodies are short lasting [24]. Therefore, the inhibits Na/Pi activity in proximal tubular opossum kid-
ney (OK) cells, while the expression of Na/Pi mRNAobservation of apoptotic cells or bodies in some post-
transplant biopsies and not in pretransplant specimens and protein increases, independent of PTH. These ef-
fects were also induced by sera from patients with ad-may indicate either that there is an increase in the time
span of apoptotic bodies or that there occurs an increase vanced chronic renal failure, but not when cells were
incubated with late posttransplant sera, suggesting thatin the proportion of cells that undergo apoptosis. This
last possibility is in accordance with the observation that persistence of a “phosphatonin” factor in the early post-
transplant period would be responsible for the hyperphos-patients showing increased apoptosis had also lower os-
teoblast surface and number. phaturia and hypophosphatemia observed after trans-
plantation. While the nature of the “phosphatonins” inSeveral mechanisms may be involved in the increased
apoptosis after renal transplantation. We found that cu- these patients has not been elucidated, recent studies
have described the potential identity of “phosphatonins”mulative dose of glucocorticoids correlated negatively
with posttransplant osteoblast surface. As mentioned in other disorders characterized by hyperphosphaturia
and hypophosphatemia, such as oncogenic osteomalaciaabove, recent studies strongly suggest that osteoblast and
osteocyte apoptosis, and inhibition of osteoblastogenesis (OOM), X-linked hypophosphatemic rickets (XLHR), and
autosomic-dominant hypophosphatemic rickets (ADHR)may play a central role in glucocorticoid-induced osteo-
porosis [13–24]. Since bone biopsies in our patients were [33–35]. One of them, fibroblast growth factor-23 (FGF-
23), induces phosphaturia and hypophosphatemia whenperformed early after transplantation, a period of maxi-
mal glucocorticoid dose, it seems possible that glucocor- administered to normal mice. Furthermore, long-term
exposure to FGF-23 by implantation of Chinese hamsterticoids may play a role in the increase of apoptosis ob-
served in many of our patients. In contrast, we did not ovary stably expressing FGF-23 into nude mice induced
hypophosphatemia and severe osteomalacia [33]. Thefind any correlation between cyclosporine and the alter-
ations of bone histology posttransplantation. fact that FGF-23 also decreases 1-hydroxylase messen-
ger mRNA [33, 34] provides an additional explanationPatients showing posttransplant apoptosis had signifi-
cantly lower serum phosphorus levels compared with for the defect of mineralization observed in these situa-
tions. Furthermore, a direct effect of FGF-23 on osteo-those without apoptosis. Furthermore, posttransplant se-
rum phosphorus correlated negatively with the number blasts was suggested by the findings of growth retarda-
tion in knockout mice, and the expression of phosphate-of apoptotic osteoblasts. In addition, there was a highly
significant correlation between osteoblast number and regulating gene with homologies to endopeptidase on
the X chromosome (PHEX) and FGF-23 in these cellsthe percentage of active osteoblasts, suggesting a role of
phosphorus in the pathogenic mechanisms leading to [36]. Another phosphaturic factor, frizzled-related pro-
tein 4 (FRP4), isolated from OOM tumors, has beenposttransplant bone disease. Indeed, hypophosphatemia
has been associated with severe alterations in bone turn- associated with expression of apoptosis-related genes
[37], but a direct induction of apoptosis has not beenover that include a decrease in osteoblast activity leading
to rickets and osteomalacia [26–28]. Our results strongly demonstrated. Therefore, although our studies suggest
that “phosphatonins” may play a role in the pathogenesissuggest a causative effect of hypophosphatemia on the
decrease in bone formation and the increased mineral- of hypophosphatemia in our patients, they may provide
a link between hypophosphatemia and alterations in os-ization lag time posttransplant. Since posttransplant hy-
pophosphatemia may be due to high levels of phospha- teoblastogenesis or osteoblast apoptosis following trans-
plantation.tonin, these results call into question the effects of
phosphatonin on osteoblast function. Finally, an interesting finding in posttransplant biop-
sies was a positive correlation between osteoblast surfaceHypophosphatemia, a frequent disorder after renal
transplantation [10, 11, 29, 30], may be contributed to and the serum levels of pre- and posttransplant PTH,
suggesting an important role of the hormone in preserv-by inappropriate phosphaturia as a consequence of per-
sistently elevated PTH levels, glucocorticoids, and rela- ing osteoblast number and activity after transplantation.
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